logo
World fertility rates in 'unprecedented decline'

World fertility rates in 'unprecedented decline'

BBC News19 hours ago

Namrata Nangia and her husband have been toying with the idea of having another child since their five-year-old daughter was born.But it always comes back to one question: 'Can we afford it?'She lives in Mumbai and works in pharmaceuticals, her husband works at a tyre company. But the costs of having one child are already overwhelming - school fees, the school bus, swimming lessons, even going to the GP is expensive.It was different when Namrata was growing up. "We just used to go to school, nothing extracurricular, but now you have to send your kid to swimming, you have to send them to drawing, you have to see what else they can do."
According to a new report by the United Nations Population Fund (UNFPA), the UN agency for reproductive rights, Namrata's situation is becoming a global norm.The agency has taken its strongest line yet on fertility decline, warning that hundreds of millions of people are not able to have the number of children they want, citing the prohibitive cost of parenthood and the lack of a suitable partner as some of the reasons.UNFPA surveyed 14,000 people in 14 countries about their fertility intentions. One in five said they haven't had or expect they won't have their desired number of children.The countries surveyed - South Korea, Thailand, Italy, Hungary, Germany, Sweden, Brazil, Mexico, US, India, Indonesia, Morocco, South Africa, and Nigeria - account for a third of the global population.They are a mix of low, middle and high-income countries and those with low and high fertility. UNFPA surveyed young adults and those past their reproductive years."The world has begun an unprecedented decline in fertility rates," says Dr Natalia Kanem, head of UNFPA."Most people surveyed want two or more children. Fertility rates are falling in large part because many feel unable to create the families they want. And that is the real crisis," she says.
"Calling this a crisis, saying it's real. That's a shift I think," says demographer Anna Rotkirch, who has researched fertility intentions in Europe and advises the Finnish government on population policy."Overall, there's more undershooting than overshooting of fertility ideals," she says. She has studied this at length in Europe and is interested to see it reflected at a global level.She was also surprised by how many respondents over 50 (31%) said they had fewer children than they wanted.The survey, which is a pilot for research in 50 countries later this year, is limited in its scope. When it comes to age groups within countries for example, the sample sizes are too small to make conclusions.But some findings are clear.In all countries, 39% of people said financial limitations prevented them from having a child.The highest response was in Korea (58%), the lowest in Sweden (19%).In total, only 12% of people cited infertility - or difficulty conceiving - as a reason for not having the number of children they wanted to. But that figure was higher in countries including Thailand (19%), the US (16%), South Africa (15%), Nigeria (14%) and India (13%)."This is the first time that [the UN] have really gone all-out on low fertility issues," says Prof Stuart Gietel-Basten, demographer at the Hong Kong University of Science and Technology.Until recently the agency focused heavily on women who have more children than they wanted and the "unmet need" for contraception.
Still, the UNFPA is urging caution in response to low fertility."Right now, what we're seeing is a lot of rhetoric of catastrophe, either overpopulation or shrinking population, which leads to this kind of exaggerated response, and sometimes a manipulative response," says Dr Kanem. "In terms of trying to get women to have more children, or fewer."She points out that 40 years ago China, Korea, Japan, Thailand and Turkey were all worried their populations were too high. By 2015 they wanted to boost fertility."We want to try as far as possible to avoid those countries enacting any kind of panicky policies," says Prof Gietel-Basten."We are seeing low fertility, population ageing, population stagnation used as an excuse to implement nationalist, anti-migrant policies and gender conservative policies," he says.UNFPA found an even bigger barrier to children than finances was a lack of time. For Namrata in Mumbai that rings true.She spends at least three hours a day commuting to her office and back. When she gets home she is exhausted but wants to spend time with her daughter. Her family doesn't get much sleep."After a working day, obviously you have that guilt, being a mom, that you're not spending enough time with your kid," she says."So, we're just going to focus on one."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

TB: India brought forward its tuberculosis elimination deadline - but can it meet it?
TB: India brought forward its tuberculosis elimination deadline - but can it meet it?

BBC News

timean hour ago

  • BBC News

TB: India brought forward its tuberculosis elimination deadline - but can it meet it?

Atul Kumar (name changed) anxiously paced the corridor of a public hospital in India's capital Delhi.A small-appliance mechanic, he was struggling to secure medicines for his 26-year-old daughter who suffers from drug-resistant tuberculosis (TB). Mr Kumar said his daughter needed 22 tablets of Monopas, an antibiotic used for treating TB, every day. "In the past 18 months, I haven't received government-supplied medicine for even two full months," he told BBC Hindi in January, months before India's declared deadline to eliminate the infectious to buy costly drugs from private pharmacies, Mr Kumar was drowning in debt. A week's supply cost 1,400 rupees ($16; £12), more than half his weekly income. After the BBC raised the issue, authorities supplied the medicines Mr Kumar's daughter needed. Federal Health Secretary Punya Salila Srivastava said that the government usually acts quickly to fix medicine access issues when Kumar's daughter is one of millions of Indians suffering from tuberculosis, a bacterial disease that infects the lungs and is spread when the infected person coughs or home to 27% of the world's tuberculosis cases, sees two TB-related deaths every three minutes. India's TB burden has long been tied to poor case detection, underfunding and erratic drug this grim reality, the country has set an ambitious goal. It aims to eliminate TB by the end of 2025, five years ahead of the global target set by the World Health Organization (WHO) and United Nations member as defined by the WHO, means cutting new TB cases by 80% and deaths by 90% compared with 2015 visits to TB centres in Delhi and the eastern state of Odisha revealed troubling gaps in the government's TB Odisha's Khordha district, around 30km (18.6 miles) from state capital Bhubaneshwar, 32-year-old day-labourer Kanhucharan Sahu is struggling to continue his two-year-old daughter's TB treatment, with government medicines unavailable for three months and private ones costing 1,500 rupees a month - an unbearable burden."We can't see her suffer anymore," he says, his voice breaking. "We even thought of abandoning her."At Odisha's local TB office, officials promised to review Sahu's case, but a staffer admitted, "We rarely get the medicines we need, so we ration them." Mr Sahu says he hasn't received the promised 1,000 rupees monthly support from the federal government and at the local TB office, officials admit to chronic shortages, leaving families like his adrift in a failing Routray, who runs the patient support group Sahyog, says medicine shortages are now routine, with government outlets often running dry. "How can we talk about ending TB with such gaps?" she are other hurdles too - for example, changing treatment centres involves navigating complex bureaucracy, a barrier that often leads to missed doses and incomplete care. This poses a major hurdle for India's vast population of migrant a hospital near Khordha, 50-year-old Babu Nayak, a sweeper who was diagnosed with TB in 2023, struggles to continue his treatment. He was regularly forced to travel 100km to his village for medicines as officials insisted he collect them from the original centre where he was diagnosed and first treated. "It became too difficult," he to travel so often, Mr Nayak stopped taking the medication altogether."It was a mistake," he admitted, after contracting TB again last year and being his hospital, no TB specialist was available, highlighting another critical gap in India's fight: a shortage of frontline health BBC shared its findings with the federal health ministry and officials in charge of the TB programme in Delhi and Odisha. There was no response despite repeated reminders.A 2023 parliamentary report showed there were many vacant roles across all levels of the TB programme, affecting diagnosis, treatment and follow-up - especially in rural and underserved vaccines help India triumph over tuberculosis?In 2018, when Prime Minister Narendra Modi brought forward India's TB elimination target to 2025, he cited the government's intensified efforts as a reason for optimism. Two years later, the Covid pandemic disrupted TB elimination efforts globally, delaying diagnosis, diverting resources and pausing routine services. Medicine shortages, staff constraints and weakened patient monitoring have further widened the gap between ambition and these challenges, India has made some the past decade, the country has reduced its tuberculosis-related mortality. Between 2015 and 2023, TB deaths declined from 28 to 22 per 100,000 people. This figure, however, is still high when compared with the global average which stands at number of reported cases has gone up, which the government credits to its targeted outreach and screening programmes. In 2024, India recorded 2.6 million TB cases, up from 2.5 million in 2023. Federal Health Minister JP Nadda recently touted innovations like handheld X-ray devices as game-changers in expanding testing. But on the ground, the picture is less optimistic."I still see some patients come to me with reports of sputum (phlegm) smear microscopy for TB, a test which has a much lower detection rate as compared to genetic tests," says Dr Lancelot Pinto, a Mumbai-based tests, which includes RT-PCR machines - widely used to diagnose HIV, influenza and most recently, Covid-19 - and Nucleic Acid Amplification Testing, also examine the sputum sample but with greater sensitivity and in a shorter the tests can reveal whether the TB strain is drug-resistant or sensitive, something that microscopic testing can't do, Dr Pinto gap, he adds, stems not just from lack of awareness but from limited access to modern tests."Genetic testing is free at government hospitals but not uniformly available, with only a few states being able to provide it."In May, Modi led a high-level review of India's TB elimination programme, reaffirming the country's commitment to defeating the the official statement notably skipped mention of the 2025 deadline. Instead, it highlighted community-driven strategies - better sanitation, nutrition and social support for TB-affected families - as key to the government has also prioritised better diagnosis, treatment and prevention at the core of its elimination approach mirrors the WHO's view of TB as a "disease of poverty". In its 2024 report, WHO chief Tedros Adhanom Ghebreyesus called it "the definitive disease of deprivation", noting how poverty, malnutrition and treatment costs trap patients in a vicious cycle. As India pushes toward its goal of eliminating the disease, deep health and social inequalities remain just six months left until India's self-imposed deadline, new complications have fallout from US President Donald Trump's withdrawal from the WHO and suspension of USAID operations has raised concerns about future funding for global TB efforts. Since 1998, USAID has invested more than $140m to help diagnose and treat TB patients in India. However, India's federal health secretary insists there is "no budgetary problem" hope lies on the horizon. Sixteen TB vaccine candidates are currently in development across the world, with the WHO projecting potential availability within five years, pending successful trials.

Drug pricing reform talks with US government lack clarity, industry executives say
Drug pricing reform talks with US government lack clarity, industry executives say

Reuters

time5 hours ago

  • Reuters

Drug pricing reform talks with US government lack clarity, industry executives say

June 10 (Reuters) - Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly (LLY.N), opens new tab and Merck (MRK.N), opens new tab said at an industry conference on Tuesday. President Donald Trump issued an executive order last month directing drugmakers to lower the prices of their medicines to align with what other countries pay. According to the order, the administration was to set "most favored nation" price targets within 30 days. The Department of Health and Human Services has said it expects drugmakers in the U.S. to set prices for their products at the lowest price paid by other high-income countries. Lilly's chief financial officer, Lucas Montarce, said that it was not clear when a resolution on the pricing reform would be achieved. "It's hard to make any assumption about when, but they haven't shared with us any details at this time," said Montarce at the Goldman Sachs' Healthcare Conference. On Monday, Pfizer's (PFE.N), opens new tab chief executive Albert Bourla had said that the meetings with the Trump administration were focused on high-level ideas and not "digging into the substance." "Conversations are ongoing. No clarity yet on where it's going to go," said Merck's CEO Robert Davis. Davis added that Merck has discussed how to share the cost of drug innovation, both in the United States and other countries, with the administration. "But how does that all translate into an actionable plan in the near term? There's still a lot of dialog happening, so that's not as clear," he said. Lilly and Merck executives said that any pricing reforms would require regulatory changes or government-to-government actions. AbbVie's (ABBV.N), opens new tab CEO also said that there was a "long way to go" before an agreement would be reached on the pricing reform.

Novo Nordisk starts new CagriSema weightloss drug trial
Novo Nordisk starts new CagriSema weightloss drug trial

Reuters

time8 hours ago

  • Reuters

Novo Nordisk starts new CagriSema weightloss drug trial

COPENHAGEN, June 10 (Reuters) - Novo Nordisk ( opens new tab has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as it tries to reassure the market of its potential after disappointing data from two previous studies. The Danish company made the announcement in an entry published on opens new tab "This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term," Novo Nordisk said in the entry.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store